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Summary
Background Data for the safety and eﬃ  cacy of new-generation drug-eluting stents at long-term follow-up, and 
speciﬁ cally in patients with ST-segment elevation myocardial infarction, are scarce. In the EXAMINATION trial, we 
compared everolimus-eluting stents (EES) with bare-metal stents (BMS) in an all-comer population with ST-segment 
elevation myocardial infarction. In this study, we assessed the 5-year outcomes of the population in the 
EXAMINATION trial.
Methods In the multicentre EXAMINATION trial, done in Italy, Spain, and the Netherlands, patients with ST-segment 
elevation myocardial infarction were randomly assigned in a 1:1 ratio to receive EES or BMS. The random allocation 
schedule was computer-generated and central randomisation (by telephone) was used to allocate patients in blocks of 
four or six, stratiﬁ ed by centre. Patients were masked to treatment assignment. At 5 years, we assessed the combined 
patient-oriented outcome of all-cause death, any myocardial infarction, or any revascularisation. Analysis was by 
intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00828087.
Findings 1498 patients were randomly assigned to receive either EES (n=751) or BMS (n=747). At 5 years, complete 
clinical follow-up data were obtained for 731 patients treated with EES and 727 treated with BMS (97% of both 
groups). The patient-oriented endpoint occurred in 159 (21%) patients in the EES group versus 192 (26%) in the BMS 
group (hazard ratio 0·80, 95% CI 0·65–0·98; p=0·033). This diﬀ erence was mainly driven by a reduced rate of 
all-cause mortality (65 [9%] vs 88 [12%]; 0·72, 0·52–0·10; p=0·047).
Interpretation Our ﬁ ndings should be taken as a point of reference for the assessment of new bioresorbable 
polymer-based metallic stents or bioresorbable scaﬀ olds in patients with ST-segment elevation myocardial infarction. 
Funding Spanish Heart Foundation.
Introduction
Percutaneous coronary intervention (PCI) is the standard 
of treatment for patients with ST-elevation myocardial 
infarction when done at specialist centres within the time 
from onset of symptoms as per guidelines.1 ST-elevation 
myocardial infarction represents both a model of a 
thrombotic setting and a challenging clinical scenario to 
test new intracoronary devices.2 In this clinical setting, 
ﬁ rst-generation drug-eluting stents (DES) reduced clinical 
and angiographic restenosis, compared with bare-metal 
stents (BMS).3–7 Conversely, these beneﬁ ts were 
counterbalanced by an increased risk of very late stent 
thrombosis,8–11 safety concerns that were conﬁ rmed on 
autopsy, and intravascular imaging studies showing 
evidence of incomplete endothelialisation, delayed arterial 
healing, and vessel remodelling because of chronic 
inﬂ ammation.12–15 The development of neotherosclerosis,16 
which might occur earlier after DES than after BMS,17 has 
also been identiﬁ ed as a potential cause.
Compared with BMS and ﬁ rst-generation DES, the 
Xience V stent (Abbott Vascular, Santa Clara, CA, USA) 
reduced rates of cardiovascular events in randomised 
controlled trials and meta-analysis at short-term 
and mid-term follow-up.18,19 The 2014 myocardial 
revascularisation guidelines recommend the use of 
second-generation DES for ST-elevation myocardial 
infarction.1 However, long-term follow-up data are 
lacking.
The EXAMINATION (clinical Evaluation of the 
Xience-V stent in Acute Myocardial INfArcTION) all-
comers trial was designed to compare clinical outcomes 
in patients with ST-elevation myocardial infarction 
receiving EES with those receiving BMS.20 At a maximum 
follow-up of 2 years, the use of EES was associated with a 
reduced rate of repeat revascularisation and stent 
thrombosis, although it did not reduce the combined 
patient-oriented primary endpoint.21,22 In this study, we 
compared 5-year clinical outcomes in patients with ST-
elevation myocardial infarction treated with EES versus 
BMS in the EXAMINATION trial,20 focusing on 
diﬀ erences between the ﬁ rst and subsequent years of 
follow-up.
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Methods
Study design and participants
The EXAMINATION study was a multicentre, 
multinational, prospective, randomised, two-arm, single-
blind, controlled trial in patients with ST-elevation 
myocardial infarction; the detailed study design has been 
previously reported.20 Brieﬂ y, the study had broad 
inclusion and few exclusion criteria to ensure an all-
comers population with ST-elevation myocardial 
infarction, representative of routine clinical practice. The 
inclusion criteria were any adult presenting with ST-
elevation myocardial infarction and meeting the following 
electrocardiograph (ECG) criteria: at least 1 mm in two or 
more standard leads, at least 2 mm in two or more 
contiguous precordial leads, or new left bundle-branch 
block within the ﬁ rst 48 h after onset of symptoms that 
required emergency PCI, and a vessel size of 
2·25–4·00 mm without other anatomical restrictions. 
Exclusion criteria were age younger than 18 years, 
pregnancy, chronic treatment with anti-vitamin K agents, 
ST-elevation myocardial infarction secondary to stent 
thrombosis, and known intolerance to aspirin, clopidogrel, 
heparin, stainless steel, everolimus, or contrast material.
12 centres in Italy, Spain, and the Netherlands 
participated in the trial. All centres received the approval 
of their medical ethics committee for the protocol and for 
the acquisition of informed consent. The study complied 
with the Declaration of Helsinki and applicable local 
requirements. All patients provided written informed 
consent for participation in the trial.
Randomisation and masking
All recruited patients were randomly allocated in a 
1:1 ratio to the EES (Xience V stent) or cobalt-chromium 
BMS (Multilink Vision stent, Abbott Vascular, 
Santa Clara, CA) groups. The allocation sequence with 
Research in context
Systematic review
We searched PubMed from Jan 10, 2005, to Aug 10, 2015, for 
complete reports of trials in which drug-eluting stents (DES) 
were compared with bare-metal stents (BMS) in patients with 
ST-elevation myocardial infarction. We found several trials 
comparing ﬁ rst-generation DES versus BMS in this speciﬁ c 
clinical setting. By narrowing our search to second-generation 
DES, we identiﬁ ed the COMFORTABLE-AMI trial of the 
comparison of biolimus-eluting stent with BMS and the 
XAMI trial of the comparison of everolimus-eluting stent 
(EES) versus ﬁ rst-generation DES. Follow-up of these studies 
was 2 years and 1 year. Additionally, we identiﬁ ed other trials 
in an all-comer population including ST-elevation myocardial 
infarction (RESOLUTE AC, LEADERS, and COMPARE trials) of 
the comparison of two diﬀ erent second-generation DES or 
second-generation versus ﬁ rst-generation DES.
Added value of this study
Our study is the ﬁ rst report of a randomised comparison of a 
second-generation DES and BMS in the clinical setting of 
ST-elevation myocardial infarction with long-term follow-up 
(up to 5 years). At 5 years, patients allocated to EES had a reduction 
in both the combined patient-oriented and device-oriented 
endpoints mainly driven by a reduction in all-cause mortality and 
revascularisation. Additionally, these results were obtained in the 
absence of very late hazards (namely stent thrombosis, target 
vessel myocardial infarction, or restenosis).
Interpretation of all the available evidence
The benefit of EES in ST-elevation myocardial infarction at 
long term is reassuring and confirms the use of second-
generation stents as the current gold standard treatment in 
this clinical context.
Figure 1: Trial proﬁ le
EES=everolimus-eluting stents. BMS=bare-metal stents. *Some patients had more than one reason for exclusion.
2148 patients assessed for eligibility
644 excluded*
145 no informed consent
70 could not comply with dual antiplatelet regimen
63 stent thrombosis
59 needed subsequent surgery
54 travelling
52 declined participation
32 terminally ill
32 inappropriate vessel size
30 on anti-vitamin K treatment
24 in another trial
16 drug misuse
90 other reasons
1504 randomly assigned
752 assigned to BMS group
5 withdrew consent
747 BMS group
14 lost to follow-up
6 withdrew consent during 
follow-up
727 analysed
752 assigned to EES group
1 withdrew consent
751 EES group
16 lost to follow-up
4 withdrew consent 
731 analysed
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block sizes of four or six was computer-generated. 
Central randomisation (by telephone) was stratiﬁ ed by 
centre. Patients were masked to treatment assignment.
Procedures
Both EES and BMS have the same design. At the index 
procedure, anticoagulation was achieved with either 
unfractionated heparin or bivalirudin. The use of 
glycoprotein IIb/IIIa inhibitors was at the discretion of the 
operator. Administration of aspirin (loading dose 
250–500 mg) and clopidogrel (loading dose ≥300 mg) was 
required before PCI for patients not on chronic antiplatelet 
treatment (neither prasugrel nor ticagrelor had become 
available at the time of recruitment). Clopidogrel 
(75 mg/day) was prescribed for at least 1 year and aspirin 
(100 mg/day) indeﬁ nitely. Manual thrombectomy followed 
by direct stenting was the recommended technique during 
PCI, although other devices could also be used if thought 
to be necessary. Operators were instructed to use only the 
randomly assigned stent type for the index procedure.
Outcomes
Primary and secondary endpoints of the study have been 
reported elsewhere.21 Brieﬂ y, the primary endpoint was 
the patient-oriented combined endpoint of all-cause death, 
any myocardial infarction, or any revascularisation at 
1 year as per the deﬁ nition by the Academic Research 
Consortium (ARC) deﬁ nition.23 The main secondary 
endpoints were the device-oriented combined endpoint of 
cardiac death, target vessel myocardial infarction, or target 
lesion revascularisation;23 all-cause and cardiac death; any 
myocardial infarction (WHO extended deﬁ nition24); target 
lesion revascularisation; target vessel revascularisation; 
and stent thrombosis (as per ARC deﬁ nitions23). All the 
above endpoints had been assessed up to the 5-year 
follow-up. Detailed deﬁ nitions of the endpoints have been 
reported elsewhere.20 Patients with multivessel disease 
needing staged PCI could also be included. Staged 
procedures had to be done within the ﬁ rst month after 
discharge and with the same stent as per randomisation.
Follow-up included a clinical visit or telephone contact 
at 30 days, 6 months, and 1 year, and then yearly contact 
for up to 5 years. No angiographic follow-up was 
mandated in the protocol.
Independent study monitors veriﬁ ed all case reports 
from data on site. Data were stored in a central database, 
which was maintained by a contract research organisation 
(Cardialysis, Rotterdam, Netherlands). A clinical event 
committee, whose members were masked to the assigned 
stent, independently adjudicated all deaths, potential 
myocardial infarctions, stent thrombosis, and 
revasc ularisation procedures.
Statistical analysis
The trial was powered for superiority of the primary 
endpoint at 1 year.20,21 The sample size calculation was 
based on a two-sided type I error rate α of 0∙05, EES to 
BMS randomisation ratio of 1:1, and a statistical power 
of at least 86% to detect a 30% reduction in the rate of 
the primary endpoint at 1 year (ie, to an approximate 
event rate of 20·5% in the control group and 14·5% in 
the EES group). For the purpose of this analysis, we 
calculated two-sided 95% CI and two-sided p values for 
EES group 
(n=751)
BMS group 
(n=747)
Hazard ratio (95% CI) p value
1-year follow-up
Primary endpoint, patient oriented* 89 (12%) 106 (14%) 0·83 (0·62–1·09) 0·19
Device-oriented endpoint† 44 (6%) 63 (8%) 0·69 (0·48–0·10) 0·0568
Death‡ 26 (3%) 26 (3%) 0·99 (0·58–1·71) 1·00
Cardiac 24 (3%) 21 (3%) 0·67 (0·32–2·04) 0·76
Vascular 1 (<1%) 3 (<1%) 0·33 (0·03–3·19) 0·37
Non-cardiovascular 1 (<1%) 2 (<1%) 0·50 (0·05–5·48) 0·62
Myocardial infarction§ 10 (1%) 15 (2%) 0·60 (0·22–1·64) 0·32
Target vessel related 8 (1%) 15 (2%) 0·44 (0·14–1·43) 0·14
Non-target vessel related 2 (<1) 0 (0%) 1·99 (0·18–21·95) 0·49
Revascularisation 60 (8%) 79 (11%) 0·75 (0·54–1·05) 0·09
Target lesion 16 (2%) 37 (5%) 0·42 (0·24–0·76) 0·0032
Target vessel 28 (4%) 51 (7%) 0·54 (0·34–0·85) 0·0077
Non-target vessel 40 (5%) 41 (5%) 1·00 (0·64–1·52) 0·90
Deﬁ nite stent thrombosis¶ 4 (1%) 14 (2%) 0·28 (0·09–0·86) 0·0183
Deﬁ nite or probable stent 
thrombosis¶
7 (1%) 19 (3%) 0·36 (0·15–0·87) 0·022
 2-year follow-up
Patient-oriented endpoint‡ 108 (14%) 129 (17%) 0·81 (0·63–1·05) 0·11
Device-oriented endpoint† 61 (8%) 82 (11%) 0·72 (0·52–1·01) 0·055
Death§ 32 (4%) 37 (5%) 0·86 (0·54–1·38) 0·52
Cardiac 28 (4%) 28 (4%) 0·99 (0·59–1·68) 1·0
Vascular 3 (<1%) 3 (<1%) 0·99 (0·20–4·92) 0·99
Non-cardiovascular 1 (<1%) 6 (<1%) 0·17 (0·02–1·37) 0·10
Myocardial infarction* 14 (2%) 18 (2%) 0·77 (0·38–1·55) 0·45
Target vessel related 11 (1%) 16 (2%) 0·68 (0·32–1·47) 0·46
Non-target vessel related 3 (<1%) 3 (<1%) 1·00 (0·20–4·93) 0·99
Revascularisation 73 (10%) 95 (13%) 0·75 (0·55–1·01) 0·05
Target lesion 22 (3%) 42 (6%) 0·51 (0·31–0·86) 0·01
Target vessel 36 (5%) 59 (8%) 0·59 (0·39–0·90) 0·009
Non-target vessel 46 (6%) 52 (7%) 0·87 (0·59–1·30) 0·51
Deﬁ nite stent thrombosis¶ 6 (1%) 16 (2%) 0·37 (0·15–0·95) 0·03
Deﬁ nite or probable stent 
thrombosis¶
10 (1%) 21 (3%) 0·47 (0·22–1·00) 0·04
3-year follow-up
Patient-oriented‡ 116 (15%) 151 (20%) 0·75 (0·59–0·95) 0·017
Device-oriented endpoint† 66 (9%) 97 (13%) 0·66 (0·48–0·90) 0·010
Death§ 36 (5%) 55 (7%) 0·65 (0·43–0·99) 0·043
Cardiac 30 (4%) 39 (5%) 0·76 (0·48–1·23) 0·27
Vascular 3 (<1%) 3 (<1%) 0·99 (0·20–4·92) 0·99
Non-cardiovascular 6 (1%) 20 (3%) 0·23 (0·07–0·80) 0·021
Myocardial infarction* 14 (2%) 13 (2%) 1·07 (0·50–2·27) 0·86
Target vessel related 10 (1%) 11 (1%) 0·90 (0·38–2·12) 0·81
Non-target vessel related 5 (<1%) 3 (<1%) 1·66 (0·40–6·94) 0·49
Revascularisation 77 (10%) 102 (14%) 0·73 (0·55–0·99) 0·040
(Table continues on next page)
Articles
360 www.thelancet.com   Vol 387   January 23, 2016
superiority for all endpoints to allow conventional 
interpretation of results.
Continuous variables are presented as mean and SD, 
and categorical data are presented as counts and 
percentages. All analyses were by intention to treat; 
patients who were lost to follow-up were censored at 
their last known contact. We used the Mantel-Cox 
method to calculate rate ratios (RR), 95% CI for 
comparisons of clinical outcomes between groups, and 
the log-rank test to calculate corresponding p values. We 
constructed survival curves for time-to-event variables 
using Kaplan-Meier estimates. Landmark analyses were 
done from 0 to 1 year and from 1 year to 5 years of 
follow-up to assess the eﬀ ect of time on the occurrence 
of events.
Subgroup analyses were the following prespeciﬁ ed 
variables: sex, age greater than 75 years, presence of 
diabetes, primary PCI, post-PCI thrombolysis in 
myocardial infarction ﬂ ow of less than 3, multivessel 
disease, ischaemia time of less than 3 h, time to ﬁ rst 
medical contact or ﬁ rst device placement of less than 
120 min, ejection fraction of less than 30%, Killip class 
greater than I, ST-segment resolution of greater than 
70%, use of aspiration thrombectomy catheters, left 
anterior descending as infarct-related artery, and need 
for staged procedure.
This trial is registered with ClinicalTrials.gov identiﬁ er, 
NCT00828087.
Role of the funding source
The funder of the study provided funding for independent 
data management and all statistical analyses by Cardialysis 
(Rotterdam, Netherlands) and had no role in the study 
design or the decision to submit for publication. The 
principal investigators had full access to the data in the 
study. The corresponding author had full responsibility for 
the decision to submit the report for publication.
Results
Between Dec 31, 2008, and May 15, 2010, 1504 patients 
with ST-elevation myocardial infarction for up to 
48 h after the onset of symptoms were recruited; 
six withdrew consent after randomisation. 1498 patients 
were randomly assigned to receive either an EES 
(n=751) or a BMS (n=747). At 5 years, complete clinical 
follow-up was obtained for 731 patients treated with 
EES and 727 treated with BMS (97% of both groups; 
ﬁ gure 1). Baseline and procedural characteristics were 
similar between the two groups21 (appendix). Use of 
dual antiplatelet therapy beyond the 1-year prescription 
time was reduced similarly in both groups during 
the follow-up (appendix). At 5 years, 57 (9%) of 
622 participants in the BMS group and 64 (10%) 
of 648 in the EES group were still on a dual antiplatelet 
regimen (appendix).
At the 5-year follow-up, the patient-oriented combined 
endpoint occurred in 159 (21%) of 751 patients in the EES 
group and 192 (26%) of 747 patients in the BMS group 
(hazard ratio [HR] 0·80; 95% CI 0·65–0·98; p=0·033; 
table). This diﬀ erence was mainly attributable to a 
signiﬁ cant reduction in the rate of all-cause death and a 
non-signiﬁ cant reduction in any revascularisation (table). 
EES group 
(n=751)
BMS group 
(n=747)
Hazard ratio (95% CI) p value
(Continued from previous page)
Target lesion 24 (3%) 47 (6%) 0·50 (0·31–0·82) 0·006
Target vessel 40 (5%) 66 (9%) 0·59 (0·40–0·87) 0·008
Non-target vessel 51 (7%) 56 (7%) 0·90 (0·62–1·32) 0·59
Deﬁ nite stent thrombosis¶ 8 (1%) 16 (2%) 0·49 (0·21–1·15) 0·10
Deﬁ nite or probable stent 
thrombosis¶
11 (1%) 21 (3%) 0·52 (0·25–1·07) 0·08
4-year follow-up
Patient-oriented‡ 134 (18%) 166 (22%) 0·78 (0·62–0·98)  0·033
Device-oriented endpoint† 76 (10%) 106 (14%) 0·70 (0·52–0·93) 0·016
Death§ 46 (6%) 67 (9%) 0·68 (0·47–0·99) 0·042
Cardiac 36 (5%) 43 (6%) 0·83 (0·53–1·29) 0·41
Vascular 3 (<1%) 4 (1%) 0·75 (0·17–3·33) 0·70
Non-cardiovascular 10 (1%) 28 (4%) 0·35 (0·15–0·82) 0·015
Myocardial infarction* 20 (3%) 16 (2%) 1·24 (0·64–2·40)  0·52
Target vessel related 13 (2%) 13 (2%) 0·99 (0·46–2·14)  0·98
Non-target vessel related 8 (1%) 4 (1%) 1·99 (0·60–6·62)  0·26
Revascularisation 86 (11%) 110 (15%) 0·76 (0·57–1·01) 0·055
Target lesion 28 (4%) 52 (7%) 0·53 (0·33–0·83) 0·006
Target vessel 44 (6%) 72 (10%) 0·59 (0·41–0·86) 0·006
Non-target vessel 58 (8%) 60 (8%) 0·96 (0·67–1·37) 0·80
Deﬁ nite stent thrombosis¶ 11 (1%) 17 (2%) 0·64 (0·30–1·64) 0·25
Deﬁ nite or probable stent 
thrombosis¶
14 (2%) 22 (3%) 0·63 (0·32–1·23) 0·17
5-year follow-up
Patient-oriented endpoint‡ 159 (21%) 192 (26%) 0·80 (0·65–0·98) 0·033
Device-oriented endpoint† 88 (12%) 113 (15%) 0·75 (0·57–0·99) 0·043
Death§ 65 (9%) 88 (12%) 0·72 (0·52–1·00) 0·047
Cardiac 47 (6%) 55 (7%) 0·84 (0·57–1·24) 0·37
Vascular 4 (1%) 5 (1%) 0·79 (0·21–2·92) 0·72
Non-cardiovascular 14 (2%) 28 (4%) 0·49 (0·26–0·92) 0·027
Myocardial infarction* 35 (5%) 27 (4%) 1·27 (0·77–2·10) 0·35
Target vessel related 21 (3%) 23 (3%) 0·90 (0·50–1·62) 0·71
Non-target vessel related 15 (2%) 6 (1%) 2·44 (0·95–6·29) 0·07
Revascularisation 93 (12%) 116 (16%) 0·77 (0·59–1·01) 0·06
Target lesion 32 (4%) 54 (7%) 0·57 (0·37–0·89) 0·012
Target vessel 49 (7%) 76 (10%) 0·62 (0·43–0·89) 0·009
Non-target vessel 62 (8%) 62 (8%) 0·98 (0·69–1·39) 0·91
Deﬁ nite stent thrombosis¶ 12 (2%) 18 (2%) 0·65 (0·31–1·36) 0·25
Deﬁ nite or probable stent 
thrombosis¶
15 (2%) 23 (3%) 0·64 (0·33–1·23) 0·18
Data are number (%), unless otherwise indicated. EES=everolimus-eluting stent. BMS=bare metal stent. 
ARC=Academic Research Consortium. *Myocardial infarction was adjudicated in accordance with WHO’s extended 
deﬁ nition.24 †Combined (hierarchical) endpoint of cardiac death, target vessel myocardial infarction, and target lesion 
revascularisation.23 ‡Combined (hierarchical) endpoint of all-cause death, any recurrent myocardial infarction, and any 
revascularisation.23 §Death was adjudicated in accordance with the ARC’s recommendations.23 ¶Stent thrombosis was 
defined in accordance with ARC’s recommendations.23
Table: Follow-up of clinical events for up to 5 years
See Online for appendix
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The overall reduction in all-cause death was attributable 
to a non-signiﬁ cant reduction in cardiac and vascular 
deaths (absolute reduction 1%) and a signiﬁ cant 
reduction in non-cardiovascular death (absolute 
reduction 2%; table). The speciﬁ c causes of non-
cardiovascular death are shown in the appendix. Most 
common causes of non-cardiac death included cancer 
and infection or sepsis. No signiﬁ cant diﬀ erences were 
noted between the groups in the rate of any myocardial 
infarction. The device-oriented combined endpoint 
occurred in 88 (12%) patients in the EES group and 
113 (15%) patients in the BMS group (HR 0·75, 95% CI 
Figure 2: Time-to-event analysis of the patient-oriented endpoint of all-cause death, any myocardial infarction, or any revascularisation over 5 years
(A) Kaplan-Meier analysis of cumulative 5-year incidence. (B) Landmark analyses for 0–1 year and 1–5 years. Error bars indicate point-wise two-sided 95% CI with a 
complementary log-log transformation. SE was calculated with the Greenwood Formula. 
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0·57–0·99; p=0·043; table). This diﬀ erence was mainly 
attributable to a signiﬁ cant reduction in the rate of target 
lesion revascularisation (table). No diﬀ erences between 
groups were noted in the rates of cardiac death and target 
vessel myocardial infarction (table).
From day 0, Kaplan-Meier curves began to diverge for 
the patient-oriented endpoint in favour of EES for up to 
1 year, and later diverged again from year 2 to year 5 
(ﬁ gure 2A, B). A test for interaction between treatment 
eﬀ ect and time (day 0 to 1 year and 1–5 years) was 
Figure 3: Time-to-event curves for the device-oriented endpoint of cardiac death, target vessel myocardial infarction, or target lesion revascularisation over 
5 years
EES=everolimus-eluting stents. BMS=bare-metal stents. (A) Kaplan-Meier analysis of cumulative 5-year incidence. (B) Landmark analyses for 0–1 year and 1–5 years. 
Error bars indicate point-wise 2-sided 95% CI with a complementary log-log transformation. SE was calculated with the Greenwood Formula.
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negative (pinteraction=0·69 for the patient-oriented outcome 
and pinteraction=0·65 for the device-oriented outcome). The 
same pattern was noted in the time-to-event curves for 
the device-oriented endpoint (ﬁ gure 3A, B). The results 
for the patient-oriented (ﬁ gure 4) and device-oriented 
endpoints (appendix) were consistent across the stratiﬁ ed 
analysis. Time-to-event curves for individual components 
of the patient-oriented and device-oriented endpoints are 
presented in the appendix. Of note, the diﬀ erence in all-
cause death was evident beyond the 2 years of follow-up 
and the diﬀ erence in target lesion revascularisation in 
the period between day 0 to 1 year.
At 5 years, the EES and BMS groups had similar rates of 
deﬁ nite stent thrombosis (2% vs 2%; HR 0·65, 95% CI 
Figure 4: Subgroup analysis of the patient-oriented endpoint of all-cause death, any myocardial infarction, and any revascularisation at 5 years in the EES and 
BMS groups
Data are n/N (%), unless otherwise indicated. EES=everolimus-eluting stents. BMS=bare-metal stents. LAD=left anterior descending artery. PCI=percutaneous coronary 
intervention. TIMI=thrombolysis in myocardial infarction. *ST-elevation myocardial infarction for less than 12 h.
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0·31–1·36; p=0·25) and of deﬁ nite or probable stent 
thrombosis (2% vs 3%; 0·64, 0·33–1·23; p=0·18; table). 
From day 0, Kaplan-Meier curves began to diverge for 
deﬁ nite or probable stent thrombosis in favour of EES for 
up to 30 days, and remained parallel thereafter (appendix). 
Interaction between day 0 to 1 year and year 1 to year 5 was 
signiﬁ cant (pinteraction=0·02). The combined endpoints of all-
cause death or deﬁ nite (76 [10%] of 751 patients vs 105 [14%] 
of 747 patients; HR 1·44, 95% CI 1·05–1·97, p=0·024) and 
all-cause death or deﬁ nite or probable stent thrombosis 
showed signiﬁ cant reductions also favouring the use of 
EES (76 [10%] vs 104 [14%]; 1·45, 1·06–1·99, p=0·020).
Discussion
In patients with ST-elevation myocardial infarction 
requiring emergency primary PCI, durable polymer-
based EES was superior to BMS in the patient-oriented 
and in the device-oriented endpoints. The beneﬁ ts of 
EES were driven by reductions in the rates of all-cause 
death, non-cardiac death, and target lesion revasc-
ularisation. The results of this landmark analysis showed 
the absence of very late (>1 year) hazards and a beneﬁ t of 
EES compared with BMS over time.
The use of these endpoints in DES trials has been 
strongly recommended by the ARC group23 and yet the 
patient-oriented endpoint was not selected as a primary 
endpoint in reported studies of stents. The global 
patient-oriented endpoint was speciﬁ cally focused on the 
patients’ outcomes rather than the speciﬁ c eﬀ ect of a 
study stent. It has the potential to show the complex 
interplay between device performance, revascularisation 
strategy, concomitant antithrombotic regimen, secondary 
prevention, residual left ventricle function, and other 
key descriptors for patients (eg, diabetes mellitus and 
renal function).
An improved global perspective is of utmost importance 
because outcomes in the context of ST-elevation 
myocardial infarction are multifactorial and often not 
directly related to the stent implanted at the index 
procedure. Diﬀ erences in the patient-oriented endpoint 
might accrue over a longer period than previously 
thought, as shown by the results in this study. We found 
no diﬀ erences in this endpoint for up to 2 years,21,22 but 
signiﬁ cant diﬀ erences were noted at 5 years. Furthermore, 
concomitant reporting of the device-oriented endpoint, as 
recommended by the ARC, might help to deﬁ ne the true 
contribution of the stent.
The superiority of the EES over BMS was slight overall 
(5% absolute reduction in the rate of the patient-oriented 
endpoint) and it was mainly attributable to reduced rate 
of all-cause death and revascularisation. The reduction in 
all-cause and non-cardiac mortality rates cannot be 
directly explained. According to the results of landmark 
analyses, there was no interaction between treatment 
eﬀ ect and time. The beneﬁ t of EES occurred immediately 
after implantation and up to 1 year and also at long-term 
follow-up beyond 2 years (ﬁ gures 2 and 3). We could 
hypothesise that the actual reduction in early stent 
thrombosis and repeated revascularisation rates might 
have improved preservation of the left ventricle ejection 
fraction, leading to improved long-term outcomes and 
reduced need for readmission to hospital as potential 
cause of further complications including infections or 
sepsis, which seemed to be the second major cause of 
non-cardiac death in our population (appendix). 
Therefore, this ﬁ nding should be further investigated and 
conﬁ rmed in trials speciﬁ cally focused on this endpoint.
Our results show the extended beneﬁ t of EES over 
BMS in terms of target lesion and target vessel 
revascularisation in patients with ST-elevation myocardial 
infarction for up to 5-years of follow-up. This ﬁ nding 
dispels any concern about a restenosis late catch-up 
phenomenon, as initially suggested for EES based on the 
2-year imaging outcome data from SPIRIT II.25
Very late hazards such as stent thrombosis or target 
vessel myocardial infarction have not been reported in the 
extended clinical follow-up. In our trial, stent thrombosis 
remained at a low level and was lower at 5 years in patients 
who received EES (2%). Of note, the beneﬁ t in stent 
thrombosis occurred mainly during the early phase (up to 
30 days) with no thrombotic late catch-up phenomenon 
thereafter (pinteraction=0·02; appendix). The overall reduction 
in the patient-oriented endpoint was consistent across all 
prespeciﬁ ed subgroups (ﬁ gure 4). Stenting did not seem 
to have an eﬀ ect in people with diabetes and the interaction 
between diabetes and treatment eﬀ ect was not signiﬁ cant.
The only diﬀ erences between the two stent platforms 
used in this trial were the presence or absence of drug 
delivery and EES had a durable polymer and co-polymer 
composed of vinylidene ﬂ uoride and hexaﬂ uoro propylene 
monomers, which might have induced healthy 
endothelialisation of the stent and some thrombo-
resistance and haemocompatibility, as suggested by the 
results of laboratory tests.26 This haemocompatibility 
could be especially relevant in the context of ST-elevation 
myocardial infarction, in which the eventual dissolution 
of the thrombus behind the struts might lead to a high 
incidence of late-acquired malapposition.27 Furthermore, 
thrombus-containing plaques, commonly found in 
patients with ST-elevation myocardial infarction, have 
been the model of delayed arterial healing after DES 
implantation. Speciﬁ cally, the mean rate of uncovered 
stents seemed to be as high as 49% in culprit lesions from 
patients with ST-elevation myocardial infarction, 
compared with 9% in stable plaques after sirolimus-
eluting stent implantation.11 In this clinical context, 
long-term presence of a durable polymer has been 
proposed as a point of origin for a chronic inﬂ ammatory 
response that might delay the healing process.12 Therefore, 
research in this ﬁ eld has been redirected toward 
biodegradable polymer-based metallic DES, polymer-free 
DES, or completely bioresorbable scaﬀ olds.28–30 Although 
these pathological ﬁ ndings were noted after implantation 
of ﬁ rst-generation DES, the use of EES has provided 
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reassuring data in imaging studies in animals and 
people31–33 that have been conﬁ rmed in a network 
meta-analysis of ST-elevation myocardial infarction.34 
However, this meta-analysis was limited by the availability 
of only two trials speciﬁ cally designed for patients with 
ST-elevation myocardial infarction (the EXAMINATION 
trial21 and the XAMI trial35 of the comparison of EES vs 
ﬁ rst-generation sirolimus-eluting stents) and by the 
shorter follow-up (1 year and 2 years). Our 5-year follow-up 
ﬁ ndings provide reassurance about safety of using a 
second-generation durable polymer stent.
Because our study was single-blind, bias cannot be 
completely ruled out. Results of this long-term follow-up 
have to be regarded as exploratory because outcomes 
were not signiﬁ cant at the time of the primary endpoint 
analysis (1 year).21 Speciﬁ cally, the beneﬁ t in reduction of 
the mortality rate with the use of EES should be thought 
of as hypothesis-generating. Further assessment in a 
properly powered trial is needed with an endpoint of 
reducing the mortality rate.
In this trial, patients with ST-elevation myocardial 
infarction were treated with aspirin and 1 year of 
clopidogrel as dual antiplatelet therapy. The potential 
role of ticagrelor or prasugrel in further prevention of 
events (eg, stent thrombosis, recurrent myocardial 
infarction, or mortality) in this context was not assessed 
because these treatments were not available at the time 
of recruitment. Thus, the potential extended beneﬁ t of 
new antiplatelet agents beyond 1 year of follow-up36 has 
not been addressed in our study.
Although trial participants might adequately represent 
the real-world population admitted with ST-elevation 
myocardial infarction, because the all-comers design 
allowed the inclusion of most patients (70%) presenting at 
our institutions,21 there are still some patients to whom the 
reported results do not apply (excluded population). Further 
long-term research in the excluded populations is needed.
Our results lay the foundation for future developments 
in stent technologies and should be taken as a point of 
reference for the assessment of new bioresorbable 
polymer-based metallic stents or bioresorbable scaﬀ olds 
in this clinical context.
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